IntriCon (IIN) Downgraded by ValuEngine

Share on StockTwits

ValuEngine cut shares of IntriCon (NASDAQ:IIN) from a buy rating to a hold rating in a report issued on Monday.

Other equities analysts also recently issued research reports about the stock. BidaskClub downgraded shares of IntriCon from a strong-buy rating to a buy rating in a research note on Tuesday, November 13th. Stifel Nicolaus dropped their price objective on shares of IntriCon from $70.00 to $45.00 and set a buy rating for the company in a research note on Friday, January 4th. Zacks Investment Research downgraded shares of IntriCon from a buy rating to a hold rating in a research note on Friday, January 4th. Finally, Dougherty & Co raised shares of IntriCon from a neutral rating to a buy rating and set a $44.00 price objective for the company in a research note on Thursday, January 3rd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $50.25.

Shares of IntriCon stock opened at $22.49 on Monday. IntriCon has a 1-year low of $17.85 and a 1-year high of $76.80. The company has a market cap of $199.60 million, a PE ratio of 35.00, a PEG ratio of 2.90 and a beta of 1.23.

IntriCon (NASDAQ:IIN) last issued its quarterly earnings results on Tuesday, February 19th. The technology company reported $0.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.07). IntriCon had a return on equity of 12.01% and a net margin of 4.76%. The firm had revenue of $30.81 million for the quarter, compared to the consensus estimate of $30.30 million. On average, research analysts forecast that IntriCon will post 0.66 earnings per share for the current year.

In related news, VP Greg Gruenhagen sold 1,500 shares of the stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $26.21, for a total value of $39,315.00. Following the completion of the transaction, the vice president now owns 4,049 shares of the company’s stock, valued at approximately $106,124.29. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 4,500 shares of company stock valued at $115,365. 21.20% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of IntriCon by 3.4% during the fourth quarter. BlackRock Inc. now owns 509,049 shares of the technology company’s stock valued at $13,428,000 after acquiring an additional 16,512 shares during the last quarter. Vanguard Group Inc increased its position in shares of IntriCon by 66.1% during the third quarter. Vanguard Group Inc now owns 467,907 shares of the technology company’s stock worth $26,296,000 after buying an additional 186,222 shares during the period. Vanguard Group Inc. increased its position in shares of IntriCon by 66.1% during the third quarter. Vanguard Group Inc. now owns 467,907 shares of the technology company’s stock worth $26,296,000 after buying an additional 186,222 shares during the period. Dimensional Fund Advisors LP increased its position in shares of IntriCon by 11.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 343,667 shares of the technology company’s stock worth $9,066,000 after buying an additional 34,031 shares during the period. Finally, Bamco Inc. NY increased its position in shares of IntriCon by 61.2% during the third quarter. Bamco Inc. NY now owns 169,217 shares of the technology company’s stock worth $9,510,000 after buying an additional 64,217 shares during the period. 64.61% of the stock is owned by hedge funds and other institutional investors.

IntriCon Company Profile

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical bio-telemetry devices, hearing healthcare, and professional audio communication devices markets.

Featured Story: Earnings Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Neutral Media Coverage Likely to Impact PetroChina  Share Price
Neutral Media Coverage Likely to Impact PetroChina Share Price
Miragen Therapeutics  Rating Increased to Buy at Zacks Investment Research
Miragen Therapeutics Rating Increased to Buy at Zacks Investment Research
OpGen  Stock Rating Lowered by Zacks Investment Research
OpGen Stock Rating Lowered by Zacks Investment Research
PFSweb  Rating Reiterated by Needham & Company LLC
PFSweb Rating Reiterated by Needham & Company LLC
Venator Materials Sees Unusually High Options Volume
Venator Materials Sees Unusually High Options Volume
Traders Purchase Large Volume of Lear Put Options
Traders Purchase Large Volume of Lear Put Options


Leave a Reply

 
© 2006-2019 Zolmax.